Objectives: Albumin and nonprotein colloids (starches, dextran, and others) are used frequently as blood volume expanders in coronary artery bypass graft (CABG) surgery. The objective of this study was to determine differences between colloids with regard to patient characteristics and mortality rates. Design and setting: Discharge data collected in the Solucient Clinical Pathways Database from 19,578 patients undergoing CABG surgery were analyzed. Measurements: Patients receiving albumin and nonprotein colloids were compared with regard to baseline patient characteristics. A multiple regression model was developed to determine if albumin use was independently associated with mortality rates. Results: Albumin was used in 8,084 cases (41.3%). The use of albumin and nonprotein colloids was not related to patient characteristics. Mortality was lower in the albumin group compared to the nonprotein colloid group (2.47% vs 3.03%, p ‫؍‬ 0.02). In the multivariable logistic regression analysis, albumin use was associated with 25% lower odds of mortality compared to nonprotein colloid use (odds ratio, 0.80; 95% confidence interval, 0.67 to 0.96). Conclusion: Colloid administration in CABG surgery was unrelated to patient characteristics. Albumin use appears to be associated with lower incidence of mortality after CABG surgery compared to nonprotein colloid use.
C
oronary artery bypass graft (CABG) surgery is a common surgical procedure in the United States, with 598,000 procedures performed annually according to American Heart Association Heart and Stroke update of 1999. 1 Blood volume expanders such as albumin and nonprotein colloids (hetastarch [6% hydroxyethyl starch] or dextran) are frequently used perioperatively to enhance intravascular blood volume, improve hemodynamics, and reduce the need for blood transfusion. 2 Cost concerns underlie a trend to replace albumin with low-cost nonprotein colloids during cardiac surgery. However, reports have shown that nonprotein colloid volume expanders are associated with impaired hemostasis, platelet dysfunction, and excessive postoperative bleeding. [3] [4] [5] [6] A recent metaanalysis 6 reported a fourfold increase in bleeding when starches were used compared to albumin. Moreover, a study by Knutson et al 4 reported a 0.6% increase in mortality associated with hetastarch use in cardiac surgery. This result did not reach statistical significance due to power limitations. By contrast, lack of albumin has been shown to be a strong predictor of mortality after CABG surgery, 7, 8 and direct protective effects of serum albumin against mortality have been reported. 9 In addition, albumin has a strong safety record with regard to hemostasis. Thus, exogenous albumin use could potentially reduce the risk of mortality and also enhance the blood volume in cases when volume expansion is a necessity. Accordingly, we sought to determine if albumin use is associated with reduced risk of mortality as compared with nonprotein colloids. We addressed this question using a large administrative data set that specifically reported information on colloid use. Despite limitations related to definitions of postoperative complications/events, administrative databases provide sample sizes that simply cannot be achieved in the clinical trial setting and are therefore particularly well suited to explorations of rare outcomes such as mortality in a surgical practice.
Materials and Methods
A subset of the Solucient Clinical Pathways Database (formerly HCIA, Inc; Baltimore, MD) that only contained discharges that involved the administration of colloids was analyzed. Information about patients who did not receive any colloid solution was not available in the database. No specific hypotheses drove data collection. One hundred eighty-two US hospitals in 1997 and 116 US hospitals in 1998 supplied discharge records. Each discharge record corresponded to a single hospitalization event. Hospitals were located in the Northeast (11.4% in 1997 and 12% in 1998), the North and Central regions (32.3% in 1997 and 40.1% in 1998), the South (47% in 1997 and 44.2% in 1998), and the West (9.3% in 1997 and 3.7% in 1998).
The database contains standard coding for specific services and procedures provided to patients (International Classification of Clinical Services). Standard procedures and discharge diagnoses were based on International Classification of Diseases, Ninth Revision (ICD-9), Clinical Modification coding. Patients who did not have cardiovascular diagnostic codes 39.0 to 42.9 and those who were Ͻ 18 years old were excluded from the study as validated by Maynard et al. 10 The final cohort undergoing CABG surgery was separated by using the 1998 clinical modification ICD-9 procedure codes for CABG surgery (36.10 to 36.19, 36.2). Patients simultaneously undergoing cardiac aneurysm excision surgery (ICD-9 codes 37.11, 37.32) and those who received both albumin and a nonprotein colloid expander were excluded. Patients who had simultaneous cardiac valve repair (ICD-9 procedure codes 35.10 to 35.12) or replacement (35.20 to 35.24) were included in the study. The final cohort after applying inclusion and exclusion criteria consisted of 19,578 patients.
Study Variables
Comorbidity profiles were created using the ICD-9 codes for myocardial infarction (MI), congestive heart failure (CHF), peripheral vascular disease (PVD), valve disease, cerebrovascular disease, COPD, gastric ulcer, hypertension, obesity, diabetes, renal failure, liver disease, and atrial fibrillation (AF). 11 Comorbidities were analyzed separately, as they were shown to have independent effects on outcomes in other studies of large administrative databases. 11 Demographic and institutional variables included age, gender, admission through emergency department (ED), teaching status, hospital volume for CABG surgery and Medicare status. High-volume hospitals were defined as those in which at least 100 procedures were performed per year. 12 Procedure-related variables included number of grafts used, simultaneous valve procedure, and mammary graft use. The mortality was defined as in-hospital and all-cause death.
Statistical Analysis
In a first stage, a descriptive analysis of the sociodemographic, institutional, and procedure-related variables in the database was performed. The prevalence of chronic comorbid conditions was also examined. The descriptive statistics were generated per treatment group. In a second stage, patients who had received albumin and those who had received nonprotein colloid solutions (starches, dextran, and others) were compared with regard to baseline characteristics, comorbid conditions, and surgical procedure-related variables using t tests, and 2 tests (bivariate analysis). Due to the large sample size, even small, clinically insignificant differences between the groups were statistically significant. 10 Thus, variable selection for the multivariable analyses was based on peer-reviewed literature and on clinical judgement. The variables such as AF, CHF, MI, and renal failure were excluded from the multivariable analyses. Their impact could not be estimated due to the fact that limited information about the timing of the occurrences was available; these conditions may have occurred postoperatively.
In a third stage, a multivariable model was constructed. Multivariable logistic regression was employed to estimate if albumin was an independent predictor of mortality after CABG surgery. Multivariable analysis was a multistage process: first the effect of albumin was estimated after adjusting for the effect of age, gender, insurance status (Medicare vs non-Medicare), hospital volume, and ED admission. Then PVD, diabetes, COPD, gastric ulcer, hypertension, and obesity were considered. In the final stage of the analysis simultaneous valve procedure, the number of grafts and mammary graft use were included. The Statistical Analysis System (release 8.02; SAS Institute; Cary, NC) was used for data management and analysis.
Results

Cohort Characteristics
Discharge data were collected from 19,578 patients who underwent CABG surgery and received either albumin or a nonprotein colloid (hetastarch or dextran) as a blood volume expander. The mean age of the cohort was 64.5 years, and 30.8% of patients were female. Over 27% of patients were admitted through the ED, and approximately 68% of patients underwent procedures at high-volume hospitals.
Comparison of Albumin and Nonprotein Colloid Groups
Albumin was used as a volume expander in 8,084 cases (41.3%). To compare patients who received albumin with those who received a nonprotein colloid, a bivariate analysis was conducted. No significant differences in age, gender, comorbid conditions, and the proportion of patients who were treated in high-volume hospitals, who were admitted to the ED, or who were receiving Medicare were observed (Table 1 ). Patients undergoing three or more grafts were slightly more likely to receive albumin (4.7% difference) than nonprotein colloids; patients receiving mammary grafts were slightly more likely (4.5% difference) to receive nonprotein colloids. However, albumin was much less frequently used in teaching hospitals. At the bivariate level, patients who received albumin also had a lower incidence of mortality (2.47% vs 3.03%) than those who received nonprotein colloids (Table 1) .
Multivariable Analysis for Mortality Rates
The reduced incidence of mortality observed in patients receiving albumin was confirmed in a multivariable analysis. Following adjustment for the effect of 16 covariates (gender, age, COPD, gastric ulcer, obesity, PVD, number of CABGs, mammary graft, valve procedure, ED admission, hospital teaching status, hospital volume, diabetes, hypertension, length of stay, payer status), multivariable logistic regression analysis showed that albumin use was associated with 25% lower odds of mortality compared to nonprotein colloid use (odds ratio [OR], 0.80; 95% confidence interval [CI], 0.67 to 0.96) [ Table 2 ]. Female gender, age, low-volume hospital, ED admission, simultaneous valve procedure, and PVD independently increased the risk of mortality, whereas mammary grafting reduced mortality. Diabetes, COPD, gastric ulcer, number of bypass grafts, Medicare status, and teaching status of the hospital were also included in the model; however, they were not independent predictors of mortality (their parameter estimates were not significant at 5% level). The parameter estimates of hypertension and teaching status of the hospital despite being significant were not robust at different stages of modeling.
Discussion
In this large retrospective study, the effect of albumin use was compared with that of nonprotein colloid use. Few clinical and demographic differences between the albumin and nonprotein colloids were observed, which is probably due to the fact that the choice of solutions in cardiac surgery is not related to patient characteristics but rather institutional practices and preferences. The only substantial difference between the groups was related to teaching status of the institution, and albumin was less frequently used in this setting.
The mortality rate was 25% lower in the patient group receiving albumin. In this multivariable analysis, the effect of 16 variables was adjusted, resulting in good control over possible confounding effects. The OR estimate from this model supported the original mortality difference between the groups. Thus, when albumin rather than nonprotein colloids was used, approximately five to six lives were saved for every 1,000 patients who underwent CABG surgery. In our subgroup analyses, we found that there was a variation of albumin effect across different subgroups. Patients with simultaneous CABG and valve procedures benefited more from albumin (OR, 0.61) than patients with isolated CABG proce- dures (OR, 0.86). Similarly, the protective effect of albumin was less strong in teaching hospitals (0.91) than in nonteaching hospitals (0.76) [ Table 3 ]. The findings presented here are supported by a number of previous studies. Engelman et al 7 showed that hypoalbuminemia is associated with high risk of mortality, early reoperation, postoperative renal failure, and prolonged ventilatory support, ICUs stay, and total length of stay after CABG surgery. Another study also supported the evidence that low albumin is a strong predictor of mortality after CABG surgery. 8 Similarly, Goldwasser and Feldman 9 reported a protective effect of albumin against mortality. This later study, however, was not specifically conducted in cardiac surgical patients, and the direct effect of albumin administration was not assessed. Finally, Knutson et al, 4 who studied bleeding and transfusion rates associated with hetastarch use (vs no hetastarch) during CABG surgery, reported a small increase in mortality (3% vs 2.4%) when starches were used.
One study has reported that mortality rates were higher for patients receiving albumin. 13 However, this meta-analysis was based on randomized trials that included critically ill patients. This study did not include CABG surgery or any other cardiac surgical patients who require urgent fluid management for surgical/trauma-related hypovolemia and hypoalbuminemia. A recent meta-analysis by Wilkes and Navickis 14 that included surgical patients reported that albumin was not associated with higher mortality rates. In the large (Ͼ 100 patients) blinded trials included in this study, albumin was in fact associated with lower mortality rates. 14 The current study confirmed previous reports of possible benefits of albumin by using a much larger and representative sample (n ϭ 19,578) that had sufficient power (number of deaths ϭ 548) to adjust for many confounding variables. Furthermore, the benefits of albumin were assessed against active controls (nonprotein colloids). Although this analysis is based on hospital discharge data, recent reports indicate that patient characteristics in administrative databases are quite similar to those in clinical registries. 11 Reduced mortality rates with albumin use rather than nonprotein colloid use may be explained by studies that have shown that hypoalbuminemia is a strong risk factor for mortality 7, 8 and by studies that associate starches with impaired hemostasis, platelet dysfunction, and excessive postoperative bleeding. Excessive bleeding can be almost four times higher when nonprotein colloids are used instead of albumin. 3, 5, 6 Postoperative bleeding and re-operation increase mortality, 15 and blood loss often necessitates blood transfusion, which is associated with risks such as transfusion reaction, sepsis, febrile reactions, immunosuppression, and viral and bacterial infections. 16 In our exploratory analyses, we found a threefold decrease (OR, 0.28; 95% CI, 0.26 to 0.32) in blood transfusion requirements in the albumin group. However, the variable for blood transfusion was categorical (yes, no), and transfusion occurred in Ͻ 15% of patients. In addition, it was not possible to determine whether this represented autologous or homologous blood transfusion; therefore, we chose to not report this finding in the current study.
Analysis of cost-effectiveness has shown that albumin administration is also a cost-effective option. Given the difference in median charges for albumin ($415) and for nonprotein colloids ($117), albumin use results in approximately $52,000 to $54,000 in charges per life saved. This estimate compares favorably with a host of alternative uses of funds in coronary heart disease. 17 Possible indirect savings are not taken into account. Further studies in this field should more accurately evaluate length of hospital stay and other outcomes that may influence cost-effectiveness.
Other Predictors of Mortality
This study confirmed the immediate short-term advantages of internal mammary artery grafts. 18 Furthermore, this study along with several others found that female gender is a significant predictor of mortality. 19 As in other large, multicenter studies, age, urgency of the operation (ED admission), PVD, 
Limitations
The use of an administrative database has limitations. Although we were aware that the nonprotein colloid group included starches or dextran, we could not separate these categories. The data used in this study represents discharge summary information. Accordingly, patients were not followed up beyond this period of time, and mortality represented all cause in-hospital mortality that could occur at any period of time. Given the same limitation, unmeasured clinical characteristics (New York Heart Association class, cardiopulmonary bypass time, systolic ejection fraction, etc.) may still confound the results. The quantity of the crystalloid solution administered in both groups was also not estimated; however, there is no reason to believe that there would be differences between the groups with regard to the amount of crystalloid solution administered. Thus, this factor is unlikely to affect the results. Data on study variables are based on ICD-9 coding, and some conditions may be underreported. Moreover, there is limited ability to learn about the severity of these conditions. Also, information on whether CHF, MI, AF, and renal failure were present before hospital admission or occurred postoperatively was not available. However, as the prevalence of these conditions was similar in both groups, the main results are unlikely to be biased. This study does not include data that explains a mechanism for the beneficial effect of albumin.
Conclusion
Colloid administration in coronary bypass surgery is unrelated to patient characteristics and is more likely to be related to institutional preferences. The use of albumin for volume expansion appears to be associated with a reduced incidence of mortality after CABG surgery when compared to nonprotein colloid treatment. Further clinical studies are warranted to substantiate these results with better definitions of variables and to develop evidence-based guidelines for colloid administration.
